Search research articles
Contact Us
Filters
Showing results (171-180 of 381) with videos related to
Page
of 39
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research
|
June 1, 2021
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
Matteo Santoni, Alessandro Rizzo, Veronica Mollica, et al.
Expert Review of Anticancer Therapy
|
June 2, 2020
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions
Maddalena Donini, Sebastiano Buti, Francesco Massari, et al.
Clinical Genitourinary Cancer
|
February 23, 2023
The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis
Fernando Sabino Marques Monteiro, Andrey Soares, Alessandro Rizzo, et al.
Microelectronic Engineering
|
December 9, 2024
Laser micromachining of tapered optical fibers for spatially selective control of neural activity
Alessandro Rizzo, Enrico Domenico Lemma, Filippo Pisano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
October 11, 2023
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data
Deniz Can Guven, Enes Erul, Yunus Kaygusuz, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
April 29, 2022
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis
Alessandro Rizzo, Veronica Mollica, Sara Merler, et al.
Immunotherapy
|
March 26, 2025
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis
Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, et al.
Expert Opinion on Investigational Drugs
|
December 14, 2020
Nivolumab: an investigational agent for the treatment of biliary tract cancer
Alessandro Di Federico, Alessandro Rizzo, Angela Dalia Ricci, et al.
Expert Opinion on Investigational Drugs
|
November 20, 2021
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
Alessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2022
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
Alessandro Rizzo, Angela Dalia Ricci, Antonio Cusmai, et al.
Page
of 39
Search research articles
Search
Showing results (171-180 of 381) with videos related to
Sort By:
Page
of 39
Expert Review of Pharmacoeconomics & Outcomes Research
|
June 1, 2021
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
Matteo Santoni, Alessandro Rizzo, Veronica Mollica, et al.
Expert Review of Anticancer Therapy
|
June 2, 2020
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions
Maddalena Donini, Sebastiano Buti, Francesco Massari, et al.
Clinical Genitourinary Cancer
|
February 23, 2023
The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis
Fernando Sabino Marques Monteiro, Andrey Soares, Alessandro Rizzo, et al.
Microelectronic Engineering
|
December 9, 2024
Laser micromachining of tapered optical fibers for spatially selective control of neural activity
Alessandro Rizzo, Enrico Domenico Lemma, Filippo Pisano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
October 11, 2023
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data
Deniz Can Guven, Enes Erul, Yunus Kaygusuz, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
April 29, 2022
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis
Alessandro Rizzo, Veronica Mollica, Sara Merler, et al.
Immunotherapy
|
March 26, 2025
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis
Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, et al.
Expert Opinion on Investigational Drugs
|
December 14, 2020
Nivolumab: an investigational agent for the treatment of biliary tract cancer
Alessandro Di Federico, Alessandro Rizzo, Angela Dalia Ricci, et al.
Expert Opinion on Investigational Drugs
|
November 20, 2021
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
Alessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2022
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
Alessandro Rizzo, Angela Dalia Ricci, Antonio Cusmai, et al.
Page
of 39